Compare NATL & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | TVTX |
|---|---|---|
| Founded | 2023 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | NATL | TVTX |
|---|---|---|
| Price | $38.74 | $40.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $42.75 | $37.21 |
| AVG Volume (30 Days) | 421.2K | ★ 1.7M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,322,000,000.00 | $435,826,000.00 |
| Revenue This Year | $2.83 | $120.02 |
| Revenue Next Year | $3.96 | $37.00 |
| P/E Ratio | $22.18 | ★ N/A |
| Revenue Growth | 0.63 | ★ 114.22 |
| 52 Week Low | $22.30 | $12.91 |
| 52 Week High | $42.23 | $42.13 |
| Indicator | NATL | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 68.40 |
| Support Level | $38.20 | $33.49 |
| Resistance Level | $39.49 | $42.13 |
| Average True Range (ATR) | 0.82 | 1.92 |
| MACD | 0.05 | 0.40 |
| Stochastic Oscillator | 77.15 | 77.66 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.